Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Global Payout, Inc. (GOHE) Leading the Way in Fintech Solutions

A fintech company focused on next-generation B2B international solutions
MoneyTrac Technology and GreenBox POS working to provide optimal payment technologies
A global financial eco-system, top-tier banking institutions and high-level financial technology partnerships

Global Payout, Inc. (OTC: GOHE) is an innovative fintech company providing fully customized comprehensive payment solutions for both domestic and international organizations transferring funds throughout the world. The focus is on next-generation B2B solutions for automating international fund transfers, payments, billing and invoicing processes. The Global Reserve Platform (“GRP”) is the company’s offering for managing financial products. GRP provides blockchain technology within virtual currency markets such as bitcoin, is currently available in 26 foreign languages, performs currency exchanges worldwide and offers KYC-compliance for all account holders and merchants.

In a news release, Global Payout CEO James Hancock shared that GOHE’s primary targets for expansion include logistics, cryptocurrency and cannabis (http://cnw.fm/w3KjO). GOHE is working hard to transform, overhaul and digitize the massive and global logistics and supply chain industry. It is focused on optimizing efficiency for its customers and partners by creating strategic technological solutions.

MoneyTrac Technology, Inc. (“MTRAC”), a subsidiary of GOHE, has entered into an exclusive partnership with GreenBox POS, LLC (“GBOX”), a blockchain company, to provide strategic sales and marketing resources. MTRAC is set to launch GBOX services in the U.S., Canada and Mexico in April 2018. GBOX’s customized payment solutions, electronic modifications and custom-built blockchain kiosk machines fall in perfectly with MTRAC’s mission of ‘Banking the Unbankable’. Since 2009, Global Payout has developed and sought out comprehensive and customized prepaid payment solutions for their customers and partners worldwide. This JV Agreement with equity and exclusivity in sales and marketing between MTRAC and GBOX positions the company to continue offering the solutions needed to run businesses with optimum efficiency (http://cnw.fm/H5gcC).

GOHE’s aim is to deliver a global financial eco-system with top-tier banking institutions through high-level financial technology partnerships. From the beginning, it has been dedicated to developing technological software solutions that have positioned the company to now address the many different needs in a changing and growing global economy. GOHE is committed to leading the way in fintech solutions.

For more information, visit the company’s website at www.GlobalPayout.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Skinvisible, Inc.’s (SKVI) Potential Merger Set to Deliver an Alternative as Opioid Crisis Deepens

Developing opioid alternative for pain treatment
Well-positioned to capture market share as an opioid substitute
Timely market entry as opioid abuse reduces U.S. life expectancy

Opioids are taking a toll on the nation. Data released by the Centers for Disease Control and Prevention (CDC) show that, for the second year in a row, life expectancy in the United States declined due to deaths from opioid overdoses. A major contributing factor to these alarming statistics has been the increasing appearance of synthetic opioid fentanyl. The drug is immensely powerful and is suspected to be the reason why many overdoses turn out to be fatal. Compounding the crisis is the double-headed problem that fentanyl, although manufactured and marketed legally, is also produced and distributed illegally. This duality offers a pernicious path to illicit use for patients introduced to prescription opioids for pain relief. Luckily, alternatives to pain management are under development. One such option will emanate from the proposed merger between Skinvisible, Inc. (OTCQB: SKVI) and Quoin Pharmaceuticals Limited. The combined entity’s proposed first product candidate, QRX001, is expected to be developed for the treatment of post-surgical pain.

The rising use of destructive opioids is reversing the gains eked out by advances in medical science. Since 1963, U.S. life expectancy has improved, as newer drugs and better procedures are keeping us alive for longer. However, owing to increasing reliance on opioids, that trend was reversed in 2015 and 2016. Drug overdoses have now surpassed heart disease as the leading cause of death for Americans under the age of 55, according to the New York Times (http://cnw.fm/Lw1Pr), and fentanyl appears to be the chief malefactor.

Developed in Belgium in the late 1950s, fentanyl is a mighty medication with an analgesic potency that’s 80 times as high as that of morphine. It was introduced into medical practice as an anesthetic in the 1960s because of its effectiveness and, in different forms, remains in extensive use today. By the mid-1970s, illicit fentanyl had begun to appear alongside heroin and cocaine as the fare of drug traffickers. It is now eclipsing those narcotics as a source of concern because of its murderous track record. While the biological effects of fentanyl are indistinguishable from those of heroin, for example, newly developed illicit analogues may be hundreds of times as potent. As a result, the possibility of overdose for a fentanyl user is significantly increased. Moreover, the crisis may get worse. Fentanyl is now commonly being added to boost the effects of heroin and cocaine, and it may even be passed off as those substances.

These disturbing developments make the need for gentler alternatives to opioids more pressing. Despite the ravage they cause, their use continues to increase. Consequently, the U.S. opioid market, currently estimated at around $12 billion, is expected to continue growing at a CAGR of 4.6 percent until 2024 (http://cnw.fm/DM2Yn).

Replacing just a fraction of that use with an option like QRX001 is likely to lift the dark cloud hanging over the nation by weakening the forces driving the opioid onslaught. QRX001, to be the lead drug candidate of the post-merger entity (Quoin Pharmaceuticals Inc.), is a single-use transdermal non-competitive NMDA receptor antagonist intended for the treatment of post-surgical pain. An N-Methyl-D-Aspartate (NMDA) receptor allows the transfer of electrical signals between the brain and the rest of the nervous system. An NMDA receptor antagonist is a drug that inhibits the ability of that NMDA receptor to accept signals, which is very useful when those signals are experienced as pain.

The highly differentiated nature of QRX001 could position it to capture a significant market share either as monotherapy or as a key component of effective multi-modal therapy. As a result, Quoin intends to apply for fast track status for QRX001.

The completion of the merger between Skinvisible and Quoin is subject to the negotiation of a definitive agreement and other customary closing conditions, including Quoin completing a financing round for clinical development.

For more information, visit the company’s website at www.Skinvisible.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Seven-Year Licensing Agreement with Cannfections Group, Inc.

Cannabis-infused chocolates and candies, such as gummies, will be manufactured using LXRP’s next-generation, patented technology to be sold in Canada and internationally, where permitted
LXRP’s goal is to partner with manufacturers who provide best-in-class products to existing large consumer groups
Licensing DehydraTECH™ is key to LXRP’s generation of revenue; LXRP aims to license its IP in all countries where its technology is patented or patent pending

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) continues to generate revenue from licensing its proprietary and patented technology DehydraTECH™, which is already patented in the U.S. and Australia. The company also has multiple patents pending in more than 40 countries globally.

Lexaria’s entry into a seven-year definitive licensing agreement with Cannfections Group, Inc. in Canada is a major step toward bringing its improved delivery methodologies to market (http://cnw.fm/U1z45). DehydraTECH promotes healthier ingestion methods and lower overall dosing. Cannfections is expected to leverage the platform by manufacturing and marketing cannabis-infused chocolates and candies for the legalized adult market.

Cannfections contract manufactures chocolate retail products for several international and domestic chocolate brands. The company believes that the agreement should lead not only to new product entries for Canadian cannabis edibles, but to exports to international markets, where permitted. In addition, the agreement permits LXRP to offer other licensee partners the option of using Cannfection’s manufacturing expertise to produce cannabis-infused chocolates and gummies powered by DehydraTECH technology.

DehydraTECH has been shown to increase intestinal absorption rates and provide for more rapid delivery of active ingredients to the bloodstream. It also offers taste-masking benefits for orally-administered molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs and nicotine.

“By licensing our technology to Cannfections, Lexaria can now offer its commercial clients the expertise of one of Canada’s oldest and most established chocolatiers utilizing next-generation DehydraTECH technology,” Chris Bunka, CEO of Lexaria, stated in a news release. “This is a long term strategic relationship meant to offer technology, value and expertise to Licensed Producers wanting to offer the highest quality chocolate edibles available in Canada once permitted under Health Canada regulations.”

For more information, visit the company’s website at www.LexariaBioscience.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Earth Science Tech, Inc. (ETST) Scientifically Advancing CBD

Company committed to scientific validation of CBD efficacy
Produces, markets and sells only the highest quality Full-Spectrum Hemp Oil containing CBD
With new subsidiaries and acquisition, future is increasingly bright

Building on vast anecdotal and mounting scientific evidence, the market for cannabidiol (CBD) products is exploding across the globe. The discovery of the human endocannabinoid system in the 1990s has intensified research and validated many of the anecdotal reports of CBD effectiveness in treating a variety of physical ailments.

Seizing on the immense market opportunity and substantiating efficacy with science, Earth Science Tech, Inc. (OTC: ETST) is focused on the science, research and studies of its high grade hemp CBD oil as a nutraceutical and dietary supplement. Earth Science already markets and sells some of the highest quality and purity Full Spectrum Hemp Oil containing CBD available. The company’s products are formulated using superior supercritical CO2 cold liquid extraction, through which the cannabinoids are kept at the rawest state possible in order to maintain essential therapeutic properties.

Earth Science believes that science is the foundation for the future of not only its high grade hemp CBD oil and its array of products, but also the entire global CBD market. In a commitment to the underlying science, Earth Science has established a research agreement with the University of Central Oklahoma and DV Biologics Laboratory to study and advance the health care benefits of its high grade hemp CBD oil. Research has already indicated that Earth Science CBD nutritional and dietary supplement products are at the top in the industrial hemp space. The company is committed to providing the public with sound scientific research and up-to-date information on the progress of studies being done on its high grade hemp CBD products.

In 2017, Earth Science launched two new subsidiaries, KannaBidioid Inc., to manufacture and distribute vapes/e-liquids and gummy edibles, and Cannabis Therapeutic Inc., to develop proprietary cannabinoid-based nutraceuticals and pharmaceutical products based on its existing CBD patent. The company also acquired Canna Inno Laboratories Inc., which will allow it access to the burgeoning Canadian market and government grants.

Earth Science’s multi-faceted, science-based approach to the development, manufacture and sale of high quality CBD products places the company in a unique and enviable position headed into 2018 and beyond. As Chief Science Officer Michel Aubé, PhD, stated in a January 3, 2018, press release (http://cnw.fm/ak2Pv), “[W]e will clearly be recognized as a leader in cannabinoids research and other health science research arena. Our future is shining bright.”

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) and Blox Labs, Inc. Near Completion of cannaBLOX White Paper

Companies in partnership to create cannaBLOX, a blockchain-based software smart contract platform for the legalized cannabis industry
cannaBLOX blockchain software is a supply chain management platform designed to ease logistical bottlenecks, minimize fraud, assist in taxation and ensure regulatory compliance
LIBFF and BLLXF have completed preliminary input and analysis in their joint phase one development of cannaBLOX

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) and Blox Labs, Inc. (CSE: BLOX) (OTC: BLLXF) have announced progress on their joint development of phase one of cannaBLOX, the blockchain-based smart contract platform for the legalized cannabis industry (http://cnw.fm/u9FqN).

Blox Labs is working to complete its white paper on cannaBLOX, and a satellite development team has been created in Eastern Europe that specializes in blockchain and decentralized application technologies. The initial framework and analysis segment of the white paper is now complete.

The white paper includes cannabis industry analysis, schematic design, project scoping and itemizing utility and process flow details. The new development team is specialized in omni-language development in Ethereum.

LIBFF is a Canada-based company which has a focus on building a portfolio of cannabis-related businesses. In this sector, it is targeting cultivation, processing and the development of CBD/THC pet and supply-chain products. Its portfolio includes a 100 percent interest in North Road Ventures and a 60 percent interest in Just Kush, strengthening LIBFF’s position as a vertically-integrated cannabis company. North Road is an emerging distributor of cultivated and manufactured cannabis products to licensed retailers. Just Kush is a late-stage applicant for Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”).

Blox Labs developments include software for blockchain, smart contracts and decentralized application technologies. It is entering the Canadian cannabis market with cannaBLOX software, a blockchain solution targeted at cannabis seed-to-sale verification.

For more information, visit the company’s website at www.LibLeaf.ca

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Skinvisible, Inc.’s (SKVI) Topical Delivery Tech Provides Effective Protection against Deadly Flu Viruses

Skinvisible’s DermSafe® hand sanitizer provides long-term protection against viruses
Patented technology delivers active ingredients topically
Company generates revenue from four income streams

An outbreak of the deadly influenza A (H3N2) virus has devastated families across the United States this winter. Traditionally, the elderly and the very young are most vulnerable to the flu, but, this time around, it is attacking people of all ages. This outbreak follows on the heels of the potent H7N9 avian influenza virus, which has the potential to spread globally, although largely confined to China at present. Hand hygiene is vital to reduce the risk of contracting these flu strains. Skinvisible, Inc. (OTCQB: SKVI) has developed a unique hand sanitizer, DermSafe®, which offers long-term protection against harmful microbes.

DermSafe® uses patented polymer delivery technology developed by Skinvisible called Invisicare®. This proprietary technology binds active ingredients to the skin to enhance their delivery and resists wash-off and rub-off for up to four hours, even with hand washing. It creates a barrier to prevent attack by viruses and damage from toxins, retaining moisture in the skin while allowing normal respiration and perspiration. Left on the skin to do their job, Invisicare® formulations eventually wear off as part of the skin’s natural exfoliation process.

All of Skinvisible’s products utilizing Invisicare® technology are non-drying, as the formulations do not contain any organic solvents such as alcohol, silicones or waxes. Enhanced delivery means a lower dosage of active ingredients is required while still offering improved efficacy, reduced skin irritation and longer duration of action. To validate its marketing claims, the company uses FDA-registered independent laboratories to verify the efficiency of its products.

Through wholly-owned subsidiary Kintari, Skinvisible has developed a range of anti-aging products, including day cream, night cream, sunscreen and hand and body lotion. All of these products use the patented Invisicare® topical delivery technology. The company has 14 global patents for over 40 skincare products powered by Invisicare®. The Kintari website (www.Kintari.com) is a marketing portal for its products, offering consumers the ability to purchase these patented products online.

Looking ahead, Skinvisible’s development pipeline using Invisicare’s topical delivery technology includes products for acne, dermatitis, skin cancer, warts and first-aid pain relief, as well as formulations with anti-aging, anti-fungal and anti-inflammatory properties. In November 2017, the company issued a letter of intent to merge with Quoin Pharmaceuticals Limited, a developer of post-surgical pain relief products that replace or reduce opioid use. Quoin is also developing a transdermal formulation for anti-depression treatment of military veterans showing suicidal tendencies related to post-traumatic stress disorder (PTSD).

Skinvisible’s business model provides four revenue streams. By licensing its formulations, the company generates research and development fees for new products. It also charges license fees to secure exclusive territorial rights to a product, while generating ongoing royalties based on a licensee’s sales. Direct revenue is generated from the sale of Kintari products and the sale of the company’s Invisicare® polymers to its clients.

For more information, visit the company’s website at www.Skinvisible.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

EVIO, Inc. (EVIO) Sets Up in California as July 2018 Mandatory Cannabis Testing Deadline Approaches

Global testing services market expected to achieve 10 percent-plus CAGR growth
California cannabis testing market also set for exponential increase
EVIO to double national testing footprint to 18 labs

California, befitting its history as part of America’s westward expansion, has earned an appellation as the ‘Wild West’ of pot. Medical marijuana, legal in the state since 1996, has been largely bypassed by quality control and safety regulations. That is about to change. To coincide with the opening of the adult recreational market, a plethora of rules and rubrics has been issued. California MMJ businesses will have until July 2018 to ensure compliance. As a result, demand for cannabis testing services in California is set to increase rapidly, a development that means EVIO, Inc. (OTCQB: EVIO), which has acquired testing facilities in Berkeley, California, is in the right place at the right time.

The supply shortfall in California cannabis testing services is rising to crisis proportions at a time when one report warns that ‘much of the marijuana sold in dispensaries in California would fail safety standards in other states’ (http://cnw.fm/7q9FU). Quality issues plague the industry, as recent examples from further afield demonstrate. A couple of MMJ companies licensed under Canada’s ACMPR were found to be using banned pesticides, and a cancer patient died after acquiring a fungal contamination, which was said to have originated in smoked marijuana.

Despite this alarming state of affairs, there are only 22 testing laboratories operating in the state (http://cnw.fm/fV7XZ). However, where there is crisis, there is also opportunity, and EVIO has been quick to recognize this. Earlier this year, the company announced that it was acquiring C3 Labs in Berkeley, California, which will give it a presence in the Bay Area to go along with its labs in Southern California and north of Sacramento. This will bring the number of labs operated by the company to nine in five states. These include four in Oregon, two in Florida, and one each in California, Colorado and Massachusetts.

Reporting on data compiled by Markets and Markets, High Times recently commented that ‘cannabis lab testing for potency, purity and detailed information such as terpene counts was worth $866 million in 2016.’ By 2021, the global testing services market is expected to hit $1.4 billion, representing a CAGR of more than 10 percent. Driven by such a powerful tailwind, EVIO is set for further revenue growth. The company saw testing services revenues for the nine months to June 30, the last reported period, climb 1,100 percent year-over-year in 2017 to $2.1 million. Now, through testing subsidiary EVIO Labs, the company plans to open 18 laboratories by the end of 2018 at locations throughout the United States.

EVIO is headed by William Waldrop, MBA, chairman and CEO. Waldrop, a co-founder of EVIO Labs’ parent company, spearheaded the acquisition of the company’s first analytical laboratory facility in Bend, Oregon. He has since grown the company to its present five labs and nine operating locations, and he is the driving force behind the nationwide rollout of EVIO Labs.

Previously, Waldrop was chairman and CEO of Newport Entertainment Group and president and COO of College Partnership, a publicly traded company that provided student services. In addition, while working as a senior manager at AirTouch Cellular, he led the team that, in just four years, built a 44-store distribution channel generating over $100 million in annual revenues. As vice president of operations for Leading Edge Broadband, he oversaw the design and roll-out of a global telecommunications sales and outreach network. Waldrop has also provided advisory services to several public companies.

For more information, visit the company’s website at www.EVIOLabs.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is Uniquely Positioned within the Cannabis Industry

Cannabis deals in Canada cross the billion-dollar mark
DehydraTech™ offers new and innovative methods of oral delivery
Committed to high quality products using revolutionary technology
The only company in the world with patents for this innovative edible technology

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) expects to benefit significantly as cannabis deals in Canada cross the billion-dollar mark in anticipation of the legalization of recreational cannabis, which is only months away (http://cnw.fm/IY0qK). Its newly developed oral digestion technology, DehydraTECH™, is a complementary layer that works with other R&D being done on cannaboids. LXRP has been awarded a patent in the U.S. and Australia, with patents pending in 40 more countries, for the improved delivery (oral or ingestible) of all non-psychoactive cannabinoids. As the only company in the world with patents for this innovative edible technology, LXRP is in a unique position to work alongside other cannabis industry players, creating partnerships rather than competitors.

DehydraTECH allows for faster delivery time, lower dosages and shorter treatment regimens. Oral ingestion of the client drug eliminates unhealthy practices of inhalation dosing. It improves the absorption rate, by as much as five to 10 times, of non-steroid anti-inflammatory drugs (NSAIDs), vitamins, cannabinoids and even nicotine. Delivery time, the time it takes from ingestion to payload molecules reaching the bloodstream, is reduced from the 60-90 minutes of current methods to a mere 15-25 minutes. High concentrations of unhealthy sugars or sweeteners are no longer needed to mask the bitter taste, and side effects are reduced, improving the bioavailability of its client drug. This provides an opportunity for new and innovative methods of oral delivery.

LXRP is committed to finding new ways to partner with companies in order to deliver high quality products, leveraging its technology that allows Lexaria to partner with, instead of compete against, other successful names in the cannabis industry. Recently, LXRP partnered with Cannfections Group Inc. to create high quality chocolate edibles using its oral technology. It continues to develop quality product lines in sports nutrition, teas, tablets, pills and beverages, using DehydraTech for optimal delivery.

For more information, visit the company’s website at www.LexariaBioscience.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

ChineseInvestors.com, Inc. (CIIX) Recognizes Untapped CBD Market for Chinese-Speaking Individuals

ChineseInvestors.com provides first platform for Chinese-centric CBD market
The company boasts real-time services in Chinese character sets
ChineseInvestors.com launched CBD navigation application

Founded in 1999, ChineseInvestors.com, Inc. (OTCQB: CIIX) aims to be a leading financial information website that provides real-time market commentary, analysis and education-related services to Chinese-speaking investors through its dynamic financial website, www.Chinesefn.com. ChineseInvestors.com, Inc. went public on the OTCQB Venture Market in January 2012, under the symbol CIIX (http://cnw.fm/RB2Yo).

Having recognized the unprecedented opportunities that lie within the American cannabis industry, the company started laying the foundations to capitalize on the ever-growing demand for cannabidiol-based nutrition and health products. The end of 2016 marked the company’s implementation of plans for its new website, its mobile application and its online distribution of CBD oils for the booming global industry of medical marijuana. Although marijuana use is illegal within the borders of China, cannabis-based oils that include hemp-based CBDs are legal. This unique opportunity opens a potential market of nearly two billion people for the company.

Following the launch of ChineseCBDoil.com in early 2017, the company noted that it was the first online CBD health products store in the Chinese language. The website shows a variety of nutritional supplements containing CBD, including soft gels, capsules and concentrates marketed to Chinese-speaking customers worldwide. It is the company’s intention to open up a retail store in the predominantly Chinese community of San Gabriel, California, which is also where the company’s headquarters is located (http://cnw.fm/0fyWG).

ChineseInvestors.com also launched the world’s first Chinese-language-based mobile cannabis navigation application. This ‘Yelp’ style social media application is set to contain a database of marijuana dispensaries and cannabis strains, along with platforms to review and discuss various cannabis products and maps that show the locations of medical and recreational cannabis dispensaries. Alongside this, the application is set to offer cannabis business summaries and reports from Los Angeles, as well as other large cities, in an effort to provide customers with access to the best recommendations for local marijuana products. The application has been approved by the Apple store and is available for download.

In an effort to assist patients with Alzheimer’s disease, epilepsy, cirrhosis of the liver and a range of other physical and mental ailments, ChineseInvestors.com will continue its focus on investment in both the distribution and the R&D of CBD medicine and health products. With the company’s base of over 100,000 users, alongside its brand value built over the past 18 years, its mission is to become the leading Chinese medical marijuana-focused publicly traded company.

China has nearly 10 million patients that suffer from epilepsy, placing it among the most common diseases that Chinese researchers are eager to cure. Currently, in China, epilepsy cannot be wholly cured, with patients relying heavily on drugs or Chinese herbs to temporarily control the illness. In the United States, epilepsy has been successfully addressed through specialized surgical treatment. However, this option comes with a high risk factor. As a result, a majority of Chinese patients are inclined to seek conservative treatment methods in the field of Western medicine. CBD oil, therefore, has a huge potential within the market space for the treatment of epileptic cases that are located in the mainland or overseas.

Regarding clinical trials and research, ChineseInvestors.com intends to further study the efficacy of CBD oil for the treatment of the above-mentioned illnesses. Apart from that, the company will invest in CBD drug R&D enterprises with the goal of developing various CBD drugs that show positive results when used to combat epilepsy and Alzheimer’s disease. The application period for new drugs of this nature in China is two to four years, which is notably shorter than that of the FDA. It is the company’s goal to be the first company in China to use CBD oil to help mitigate the suffering of patients with epilepsy and Alzheimer’s disease.

The company also offers support services to its various partners, consultative services to smaller private companies that are considering becoming public entities and advertising and public relations-related support services.

With the further legalization of medical marijuana supported by studies, greater market sizes can be expected. With fewer drug side effects and further drug development, it is likely that the number of CBD products will increase, with more people likely to opt for these safer treatments. On a wider scale the problem of acute and chronic pain can be combatted, resulting in fewer production losses in the workplace.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Marijuana Company of America Inc. (MCOA) in CBD Sector for the Long Haul

Goldman Small Cap Research forecasts overall CBD market to grow to $1.15 billion within the next three years
MCOA’s hempSMART product line drives new industrial hemp-based CBD products to consumers
Industrial hemp offers a non-psychoactive, less controversial alternative to cannabis

Advocates and investors riding the current cannabis policy roller coaster are turning an optimistic eye to the industrial hemp sector, as its cannabis industry sibling battles for respectability and legalization in the United States.

Over the last three years, Marijuana Company of America Inc. (OTC: MCOA) has observed the political changes in the U.S., with regard to hemp and cannabis regulation at the local, state and federal levels. With this knowledge, the company is navigating its way through multiple state regulatory systems, court decisions and public opinion to build a market position to develop and drive innovative product development and distribution.

MCOA delivers turnkey products and services to consumers in U.S. states where the cannabis plant’s derivatives have been legalized. While federal drug policy continues to target state-by-state normalization of cannabis for medicinal and recreational use, MCOA’s hempSMART subsidiary is turning out branded products containing industrial hemp-derived, non-psychoactive cannabidiol (CBD) formulations for retail distribution via an affiliate marketing model.

Although 2018 began with the advancement of new state laws legalizing cannabis and hemp – most notably in California, the world’s fifth largest economy – Attorney General Jeff Sessions reaffirmed on January 4, 2018, that cannabis remains illegal under federal law. Sessions concurrently rescinded previous Obama-era federal prosecutorial guidance on state-legalized cannabis and hemp that allowed states having strong and effective regulatory and enforcement systems the discretion to regulate the production and distribution of cannabis and hemp, as long as the state-enacted rules were consistent with federal priorities. Cue multiple lawsuits around the country and Congressional debate over the propriety of existing cannabis laws. These repeated flare-ups in drug policy have left many cannabis investors nervous (http://cnw.fm/uf7JO), but other industry insiders have seen the cannabis debate as a boon to the less controversial industrial hemp plant, which contains less than 0.3 percent THC.

In 2004, the Hemp Industry Association won a Ninth Circuit Court decision to allow hemp products with less than 0.3 percent THC to be distributed legally, and hemp production was legalized nationwide for university research under the 2014 Farm Bill.

MCOA has now been an active player in the North American cannabis and hemp markets for the past three years (http://cnw.fm/Gyt53). The company has ensured, via clear and regular communications with the markets, customers, affiliates and media, that the development of hempSMART’s range of non-psychoactive products has been transparent, informed and compliant. hempSMART’s new take on wellness products include formulations for the brain, pain and Full Spectrum Drops. Newly-launched products include pain cream and, for our four-legged friends, Pet Drops.

MCOA also recently partnered with Convenient Hemp Mart, LLC to develop the “BeniHemp” CBD brand. Currently in development, BeniHemp will be targeted for sale in convenience stores, gas stations, smoke shops and similar types of small retail businesses focused on the impulse buyer, with its products located at the cash register. The BeniHemp brand is expected to offer a range of topicals, tinctures and edibles. With its unique national marketing and distribution plans, BeniHemp will work with its partners to create recognition for CBD wellness and personal care products.

On February 15, 2018, Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, released a white paper (http://cnw.fm/KG6Fh) in which it predicts that the overall CBD market in the U.S. will grow from a base of $262 million in 2016 to something exceeding $1.15 billion by 2020.

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net